Vizsgálati helyszín
Siteman Cancer Center
St Louis, Missouri 63110, Egyesült ÁllamokMég nincs intézményhez kötve
- 22futó vizsgálat
- 3lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 25 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 1/2. fázis8 vizsgálat
- 2. fázis7 vizsgálat
- 1. fázis4 vizsgálat
- 3. fázis4 vizsgálat
- 2/3. fázis2 vizsgálat
- Állapot
- Toboroz13 vizsgálat
- Fut, nem toboroz9 vizsgálat
- Lezárult3 vizsgálat
- Fő szponzor
- Pfizer8 vizsgálat
- Amgen2 vizsgálat
- Exelixis2 vizsgálat
- Gilead Sciences2 vizsgálat
- Novartis Pharmaceuticals2 vizsgálat
- és még 9
Futó vizsgálatok
Toboroz
Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms
NCT07684170· 2. fázis· Compass Therapeutics· Forrás
Contact: Sara Mitchum
Toboroz
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
NCT07566156· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
NCT07421700· 1/2. fázis· Pfizer· Forrás
Toboroz
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT07227415· 1/2. fázis· Pfizer· Forrás
Toboroz
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338· 1/2. fázis· Revolution Medicines, Inc.· Forrás
Contact: Alexis Cotton
Toboroz
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
NCT07227012· 1/2. fázis· Pfizer· Forrás
Toboroz
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
NCT07037758· 1. fázis· Amgen· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· 3. fázis· Pfizer· Forrás
Toboroz
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755· 2/3. fázis· Exelixis· Forrás
Contact: Exelixis Clinical Trials
Fut, nem toboroz
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
NCT06898957· 1. fázis· Amgen· Forrás
Toboroz
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
NCT06926920· 1/2. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
NCT06840483· 2. fázis· BicycleTx Limited· Forrás
Fut, nem toboroz
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
NCT06727565· 2. fázis· Gilead Sciences· Forrás
Toboroz
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
NCT06785636· 1/2. fázis· Pathos AI, Inc.· Forrás
Contact: Hannah Black
Fut, nem toboroz
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· 3. fázis· Pfizer· Forrás
Toboroz
Study of XB010 in Subjects With Solid Tumors
NCT06545331· 1. fázis· Exelixis· Forrás
Contact: Exelixis Clinical Trials
Fut, nem toboroz
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
NCT06447662· 1. fázis· Pfizer· Forrás
Fut, nem toboroz
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
NCT05548127· 1/2. fázis· Pfizer· Forrás
Fut, nem toboroz
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
NCT05384587· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
NCT05256290· 1/2. fázis· Black Diamond Therapeutics, Inc.· Forrás
Fut, nem toboroz
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
NCT04430738· 2. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Toboroz
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796· 2/3. fázis· Celgene· Forrás
Contact: Ravi Vij, Site 01176
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek